Marta Viana-Pereira

  • Clinical Oncology
  • Oncobiology
  • Signaling pathways
  • Targeted therapies
  • Prognostic biomarkers
  • Therapeutic biomarkers
  • Therapeutic Resistance
  • 3D cell culture models

Marta Viana-Pereira graduated in Applied Biology at University of Minho, School of Sciences in 2005. Started working on Cancer Research in 2006, at School of Medicine/Life and Health Sciences Research Institute (ICVS), University of Minho. In 2007 started her PhD, granted a fellowship from FCT (Ref: SFRH/BD/29145/2006), with the title “Molecular Genetics of Paediatric versus Adult Brain Tumours”, at School of Medicine/ICVS, University of Minho, Braga, Portugal and Institute of Cancer Research, London, UK (Supervisors: Rui Manuel Reis, University of Minho and Dr. Chris Jones, Institute of Cancer Research). In 2011, post-doctoral fellow at ICVS/UMinho (supervision of Rui Manuel Reis), on “Identification of novel target genes in microsatellite-unstable brain tumours”. In 2019 Junior Researcher at ICVS/UMinho working on the project “Deciphering the tumorigenic role of the tumour suppressor gene SPINT2 in solid tumours”. In 2019 completed the Master Degree in Medicine at Instituto de Ciências Biomédicas Abel Salazar (ICBAS), University of Porto, Portugal. In 2021 started Residency in Medical Oncology at Hospital de Braga, Portugal. Her expertise in cancer research focused on genetic instability and cancer biomarkers, mostly on brain tumors and melanoma, but overall, across distinct tumor types, having acquired broad experience in the Oncobiology research field.

Scientific Highlights

1-Pereira MS, Celeiro SP, Costa AM, Pinto F, Popov S, Almeida GC, Amorim J, Pires MM, Pinheiro C, Lopes JM, Honavar M, Costa P, Pimentel J, Jones C, Reis RM, Viana-Pereira M. Loss of SPINT2 frequently occurs in glioma, leading to increased growth and invasion via MMP2. Cellular Oncology, 2020;43(1):107-121. 2- Viana-Pereira M, Moreno D, Linhares P, Amorim J, Nabiço R, Costa S, Vaz R, Reis RM. Replication of GWAS identifies RTEL1, CDKN2A/B, and PHLDB1 SNPs as risk factors in Portuguese gliomas patients. Molecular Biology Reports, 2020; 47(2):877-886. 3- Pereira MS, de Almeida GC, Pinto F, Viana-Pereira M, Reis RM. SPINT2 Deregulation in Prostate Carcinoma. Journal of Histochemistry and Cytochemistry, 2016, 64(1):32-41. 4 – Linhares P*, Viana-Pereira M*, Ferreira M, Amorim J, Nabiço R, Pinto F, Costa S, Vaz R and Reis RM. Genetic Variants of Vascular Endothelial Growth Factor (VEGF) Predict Risk and Survival of Gliomas. Tumor Biology, 2018;40(3):1010428318766273. 5 – Book chapter: 3D culture systems as models for solid tumors and cancer metabolism (Biomaterials for 3D Tumor Modeling, 2020)